Recent Approvals for Cholangiocarcinoma Treatment
While at the 2023 Great Debates and Updates in Gastrointestinal Malignancies meeting in Chicago, Milind Javle, MD, MD Anderson Cancer Center at the University of Texas, Houston, TX, reviews the latest FDA approvals in the cholangiocarcinoma space.
Dr Javle mentions IDH1-, FGFR-, and BRAF-inhibitors as well as other targeted agents that have been approved by the FDA and included in the NCCN guidelines for the treatment of cholangiocarcinoma.
Transcript:
It's wonderful to be here in Chicago, to discuss cholangiocarcinoma, a disease that is unfortunately rapidly increasing in incidence.
This field has changed quite dramatically with several drug approvals in the last three years. This has been possible due to advent of molecular therapy with FGFR inhibitors, IDH1 inhibitors, and several others such as BRAF inhibitors, immunotherapy, making it into the NCCN guidelines.
The recent approvals have included ivosidenib for IDH1 inhibitors. For FGFR inhibitors, we have approvals for pemigatinib and futibatinib. Infigratinib was approved before, no longer is being developed. And in terms of other targeted agents approved for in the NCCN guidelines, they include dabrafenib and trametinib for BRAF-V600E. And some rare situations, for instance, for RET fusions, NTRK fusions, we have targeted drugs available.
